

Kratom Adjustments

2026 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Michael K. McKell

House Sponsor:

LONG TITLE**Committee Note:**

The Health and Human Services Interim Committee recommended this bill.

Legislative Vote: 15 voting for 0 voting against 4 absent

General Description:

This bill amends provisions related to kratom.

Highlighted Provisions:

This bill:

- repeals the Kratom Consumer Protection Act; and
- schedules alkaloids found in or derived from kratom as schedule I controlled substances.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:**AMENDS:****58-37-4**, as last amended by Laws of Utah 2025, Chapter 216**REPEALS:****4-45-101**, as enacted by Laws of Utah 2019, Chapter 329**4-45-102**, as enacted by Laws of Utah 2019, Chapter 329**4-45-103**, as enacted by Laws of Utah 2019, Chapter 329**4-45-104**, as enacted by Laws of Utah 2019, Chapter 329**4-45-105**, as enacted by Laws of Utah 2019, Chapter 329**4-45-106**, as enacted by Laws of Utah 2019, Chapter 329**4-45-107**, as enacted by Laws of Utah 2019, Chapter 329**4-45-108**, as enacted by Laws of Utah 2019, Chapter 329

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **58-37-4** is amended to read:

58-37-4 . Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl

(N-[1-(1-methyl-2-phenethyl)-4-piperidiny]-N-phenylacetamide);

(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

(C) Acetylmethadol;

(D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);

(E) Allylprodine;

(F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(G) Alphameprodine;

(H) Alphamethadol;

(I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

(J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidiny]-N-phenylpropanamide);

(K) Benzylpiperazine;

(L) Benzethidine;

(M) Betacetylmethadol;

(N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidiny]-N-phenylpropanamide);

(O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidiny]-N-phenylpropanamide;

(P) Betameprodine;

- 65 (Q) Betamethadol;
66 (R) Betaprodine;
67 (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidiny)-N-phenylbutyramide);
68 (T) Clonitazene;
69 (U) Cyclopropyl fentanyl
70 (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
71 (V) Dextromoramide;
72 (W) Diampromide;
73 (X) Diethylthiambutene;
74 (Y) Difenoxin;
75 (Z) Dimenoxadol;
76 (AA) Dimepheptanol;
77 (BB) Dimethylthiambutene;
78 (CC) Dioxaphetyl butyrate;
79 (DD) Dipipanone;
80 (EE) Ethylmethylthiambutene;
81 (FF) Etizolam
82 (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
83 (GG) Etonitazene;
84 (HH) Etoxidine;
85 (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
86 furan-2-carboxamide);
87 (JJ) Furethidine;
88 (KK) Hydroxypethidine;
89 (LL) Ketobemidone;
90 (MM) Levomoramide;
91 (NN) Levophenacetylmorphan;
92 (OO) Methoxyacetyl fentanyl
93 (2-Methoxy-N-(1-phenylethylpiperidin-4-yl)-N-acetamide);
94 (PP) Morpheridine;
95 (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
96 (RR) Noracymethadol;
97 (SS) Norlevorphanol;
98 (TT) Normethadone;

- 99 (UU) Norpipanone;
100 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
101 propanamide);
102 (WW) Para-fluoroisobutyryl fentanyl
103 (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
104 (XX) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
105 (YY) Phenadoxone;
106 (ZZ) Phenampromide;
107 (AAA) Phenibut;
108 (BBB) Phenomorphan;
109 (CCC) Phenoperidine;
110 (DDD) Piritramide;
111 (EEE) Proheptazine;
112 (FFF) Properidine;
113 (GGG) Propiram;
114 (HHH) Racemoramide;
115 (III) Tetrahydrofuran fentanyl
116 (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
117 (JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
118 (KKK) Tianeptine;
119 (LLL) Tilidine;
120 (MMM) Trimeperidine;
121 (NNN) 3-methylfentanyl, including the optical and geometric isomers
122 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
123 (OOO) 3-methylthiofentanyl
124 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
125 (PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
126 known as U-47700; and
127 (QQQ) 4-cyano CUMYL-BUTINACA.
128 (ii) Unless specifically excepted or unless listed in another schedule, any of the
129 following opium derivatives, their salts, isomers, and salts of isomers when the
130 existence of the salts, isomers, and salts of isomers is possible within the specific
131 chemical designation:
132 (A) Acetorphine;

- 133 (B) Acetyldihydrocodeine;
134 (C) Benzylmorphine;
135 (D) Codeine methylbromide;
136 (E) Codeine-N-Oxide;
137 (F) Cyprenorphine;
138 (G) Desomorphine;
139 (H) Dihydromorphine;
140 (I) Drotebanol;
141 (J) Etorphine (except hydrochloride salt);
142 (K) Heroin;
143 (L) Hydromorphenol;
144 (M) Methyldesorphine;
145 (N) Methylhydromorphine;
146 (O) Morphine methylbromide;
147 (P) Morphine methylsulfonate;
148 (Q) Morphine-N-Oxide;
149 (R) Myrophine;
150 (S) Nicocodeine;
151 (T) Nicomorphine;
152 (U) Normorphine;
153 (V) Pholcodine; and
154 (W) Thebacon.
- 155 (iii) Unless specifically excepted or unless listed in another schedule, any material,
156 compound, mixture, or preparation which contains any quantity of the following
157 hallucinogenic substances, or which contains any of their salts, isomers, and salts
158 of isomers when the existence of the salts, isomers, and salts of isomers is possible
159 within the specific chemical designation; as used in this Subsection (2)(a)(iii)
160 only, "isomer" includes the optical, position, and geometric isomers:
- 161 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α
162 -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
163 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
164 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
165 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
166 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;

- 167 2C-B, Nexus;
- 168 (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- α
- 169 -methylphenethylamine; 2,5-DMA;
- 170 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
- 171 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- α
- 172 -methylphenethylamine; paramethoxyamphetamine, PMA;
- 173 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
- 174 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
- 175 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
- 176 (I) 3,4-methylenedioxy amphetamine;
- 177 (J) 3,4-methylenedioxymethamphetamine (MDMA);
- 178 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
- 179 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE,
- 180 MDEA;
- 181 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
- 182 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy
- 183 MDA;
- 184 (M) 3,4,5-trimethoxy amphetamine;
- 185 (N) Bufotenine, some trade and other names: 3-(β
- 186 -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;
- 187 N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
- 188 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
- 189 (P) Dimethyltryptamine, some trade or other names: DMT;
- 190 (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6 β
- 191 ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]
- 192 azepino [5,4-b] indole; Tabernanthe iboga;
- 193 (R) Lysergic acid diethylamide;
- 194 (S) Marijuana;
- 195 (T) Mescaline;
- 196 (U) Parahexyl, some trade or other names:
- 197 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
- 198 Synhexyl;
- 199 (V) Peyote, meaning all parts of the plant presently classified botanically as
- 200 *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any

201 extract from any part of such plant, and every compound, manufacture, salts,
202 derivative, mixture, or preparation of such plant, its seeds or extracts
203 (Interprets 21 USC 812(c), Schedule I(c) (12));
204 (W) N-ethyl-3-piperidyl benzilate;
205 (X) N-methyl-3-piperidyl benzilate;
206 (Y) Psilocybin;
207 (Z) Psilocyn;
208 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
209 (cannabis plant), except for marijuana as defined in Subsection 58-37-2
210 (1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the
211 cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic
212 substances, derivatives, and their isomers with similar chemical structure and
213 pharmacological activity to those substances contained in the plant, such as the
214 following: Δ^1 cis or trans tetrahydrocannabinol, and their optical isomers Δ^6 cis or
215 trans tetrahydrocannabinol, and their optical isomers $\Delta^3,4$ cis or trans
216 tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
217 substances is not internationally standardized, compounds of these structures,
218 regardless of numerical designation of atomic positions covered;
219 (BB) Ethylamine analog of phencyclidine, some trade or other names:
220 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
221 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
222 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
223 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
224 (DD) Thiophene analog of phencyclidine, some trade or other names:
225 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,
226 TPCP, TCP; and
227 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
228 (iv) Unless specifically excepted or unless listed in another schedule, any material
229 compound, mixture, or preparation which contains any quantity of the following
230 substances having a depressant effect on the central nervous system, including its
231 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
232 salts of isomers is possible within the specific chemical designation:
233 (A) Mecloqualone; and
234 (B) Methaqualone.

- (v) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:
- (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine;
 - (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
 - (C) Fenethylamine;
 - (D) Methcathinone, some other names: 2-(methyldamino)-propionphenone; alpha-(methyldamino)propionphenone; 2-(methyldamino)-1-phenylpropan-1-one; alpha-N-methyldaminopropionphenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of optical isomers;
 - (E) (±)cis-4-methyldaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
 - (F) N-ethylamphetamine; and
 - (G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- (vi) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including their optical isomers, salts, and salts of isomers, subject to temporary emergency scheduling:
- (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
 - (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- (vii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
- (viii) Unless specifically excepted or unless listed in another schedule, any alkaloids found in or derived from *Mitragyna speciosa*, including synthetic alkaloids, homologs, analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation.

(b) Schedule II:

- (i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from

substances of vegetable origin, or independently by means of chemical synthesis,
or by a combination of extraction and chemical synthesis:

(A) Opium and opiate, and any salt, compound, derivative, or preparation of
opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmeferene,
naloxone, and naltrexone, and their respective salts, but including:

(I) Raw opium;

(II) Opium extracts;

(III) Opium fluid;

(IV) Powdered opium;

(V) Granulated opium;

(VI) Tincture of opium;

(VII) Codeine;

(VIII) Ethylmorphine;

(IX) Etorphine hydrochloride;

(X) Hydrocodone;

(XI) Hydromorphone;

(XII) Metopon;

(XIII) Morphine;

(XIV) Oxycodone;

(XV) Oxymorphone; and

(XVI) Thebaine;

(B) Any salt, compound, derivative, or preparation which is chemically equivalent
or identical with any of the substances referred to in Subsection (2)(b)(i)(A),
except that these substances may not include the isoquinoline alkaloids of
opium;

(C) Opium poppy and poppy straw;

(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
and any salt, compound, derivative, or preparation which is chemically
equivalent or identical with any of these substances, and includes cocaine and
ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
whether derived from the coca plant or synthetically produced, except the
substances may not include decocainized coca leaves or extraction of coca
leaves, which extractions do not contain cocaine or ecgonine; and

(E) Concentrate of poppy straw, which means the crude extract of poppy straw in

303 either liquid, solid, or powder form which contains the phenanthrene alkaloids
304 of the opium poppy.

305 (ii) Unless specifically excepted or unless listed in another schedule, any of the
306 following opiates, including their isomers, esters, ethers, salts, and salts of
307 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
308 salts is possible within the specific chemical designation, except dextrorphan and
309 levopropoxyphene:

310 (A) Alfentanil;

311 (B) Alphaprodine;

312 (C) Anileridine;

313 (D) Bezitramide;

314 (E) Bulk dextropropoxyphene (nondosage forms);

315 (F) Carfentanil;

316 (G) Dihydrocodeine;

317 (H) Diphenoxylate;

318 (I) Fentanyl;

319 (J) Isomethadone;

320 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,
321 levomethadyl acetate, or LAAM;

322 (L) Levomethorphan;

323 (M) Levorphanol;

324 (N) Metazocine;

325 (O) Methadone;

326 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;

327 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
328 1-diphenylpropane-carboxylic acid;

329 (R) Pethidine (meperidine);

330 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

331 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;

332 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

333 (V) Phenazocine;

334 (W) Piminodine;

335 (X) Racemethorphan;

336 (Y) Racemorphan;

- 337 (Z) Remifentanyl; and
338 (AA) Sufentanyl.
- 339 (iii) Unless specifically excepted or unless listed in another schedule, any material,
340 compound, mixture, or preparation which contains any quantity of the following
341 substances having a stimulant effect on the central nervous system:
342 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
343 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
344 (C) Phenmetrazine and its salts; and
345 (D) Methylphenidate.
- 346 (iv) Unless specifically excepted or unless listed in another schedule, any material,
347 compound, mixture, or preparation which contains any quantity of the following
348 substances having a depressant effect on the central nervous system, including its
349 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
350 salts of isomers is possible within the specific chemical designation:
351 (A) Amobarbital;
352 (B) Glutethimide;
353 (C) Pentobarbital;
354 (D) Phencyclidine;
355 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
356 1-piperidinocyclohexanecarbonitrile (PCC); and
357 (F) Secobarbital.
- 358 (v)(A) Unless specifically excepted or unless listed in another schedule, any
359 material, compound, mixture, or preparation which contains any quantity of
360 Phenylacetone.
361 (B) Some of these substances may be known by trade or other names:
362 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
- 363 (vi) Nabilone, another name for nabilone: (\pm
364)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
365 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 366 (vii) A drug product or preparation that contains any component of marijuana,
367 including tetrahydrocannabinol, and is approved by the United States Food and
368 Drug Administration and scheduled by the Drug Enforcement Administration in
369 Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 370 (c) Schedule III:

- (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- (A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;
 - (B) Benzphetamine;
 - (C) Chlorphentermine;
 - (D) Clortermine; and
 - (E) Phendimetrazine.
- (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
- (A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which are not listed in any schedule;
 - (B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs which is approved by the United States Food and Drug Administration for marketing only as a suppository;
 - (C) Any substance which contains any quantity of a derivative of barbituric acid or any salt of any of them;
 - (D) Chlorhexadol;
 - (E) Buprenorphine;
 - (F) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under the federal Food, Drug, and Cosmetic Act, Section 505;
 - (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

(H) Lysergic acid;

(I) Lysergic acid amide;

(J) Methyprylon;

(K) Sulfondiethylmethane;

(L) Sulfonethylmethane;

(M) Sulfonmethane; and

(N) Tiletamine and zolazepam or any of their salts, some trade or other names for

a tiletamine-zolazepam combination product: Telazol, some trade or other

names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade

or other names for zolazepam:

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]

[1,4]-diazepin-7(1H)-one, flupyrzapon.

(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in

a U.S. Food and Drug Administration approved drug product, some other names

for dronabinol:

(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,

or (-)-delta-9-(trans)-tetrahydrocannabinol.

(iv) Nalorphine.

(v) Unless specifically excepted or unless listed in another schedule, any material,

compound, mixture, or preparation containing limited quantities of any of the

following narcotic drugs, or their salts calculated as the free anhydrous base or

alkaloid:

(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90

milligrams per dosage unit, with an equal or greater quantity of an isoquinoline

alkaloid of opium;

(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90

milligrams per dosage unit, with one or more active non-narcotic ingredients in

recognized therapeutic amounts;

(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not

more than 15 milligrams per dosage unit, with a fourfold or greater quantity of

an isoquinoline alkaloid of opium;

(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not

more than 15 milligrams per dosage unit, with one or more active, non-narcotic

ingredients in recognized therapeutic amounts;

- 439 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
440 than 90 milligrams per dosage unit, with one or more active non-narcotic
441 ingredients in recognized therapeutic amounts;
- 442 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
443 than 15 milligrams per dosage unit, with one or more active, non-narcotic
444 ingredients in recognized therapeutic amounts;
- 445 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
446 or not more than 25 milligrams per dosage unit, with one or more active,
447 non-narcotic ingredients in recognized therapeutic amounts; and
- 448 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
449 with one or more active, non-narcotic ingredients in recognized therapeutic
450 amounts.

451 (vi) Unless specifically excepted or unless listed in another schedule, anabolic
452 steroids including any of the following or any isomer, ester, salt, or derivative of
453 the following that promotes muscle growth:

- 454 (A) Boldenone;
- 455 (B) Chlorotestosterone (4-chlortestosterone);
- 456 (C) Clostebol;
- 457 (D) Dehydrochlormethyltestosterone;
- 458 (E) Dihydrotestosterone (4-dihydrotestosterone);
- 459 (F) Drostanolone;
- 460 (G) Ethylestrenol;
- 461 (H) Fluoxymesterone;
- 462 (I) Formebolone (formebolone);
- 463 (J) Mesterolone;
- 464 (K) Methandienone;
- 465 (L) Methandranone;
- 466 (M) Methandriol;
- 467 (N) Methandrostenolone;
- 468 (O) Methenolone;
- 469 (P) Methyltestosterone;
- 470 (Q) Mibolerone;
- 471 (R) Nandrolone;
- 472 (S) Norethandrolone;

- 473 (T) Oxandrolone;
474 (U) Oxymesterone;
475 (V) Oxymetholone;
476 (W) Stanolone;
477 (X) Stanozolol;
478 (Y) Testolactone;
479 (Z) Testosterone; and
480 (AA) Trenbolone.
- 481 (vii) Anabolic steroids expressly intended for administration through implants to
482 cattle or other nonhuman species, and approved by the Secretary of Health and
483 Human Services for use, may not be classified as a controlled substance.
- 484 (viii) A drug product or preparation that contains any component of marijuana,
485 including tetrahydrocannabinol, and is approved by the United States Food and
486 Drug Administration and scheduled by the Drug Enforcement Administration in
487 Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 488 (ix) Nabiximols.
- 489 (d) Schedule IV:
- 490 (i) Unless specifically excepted or unless listed in another schedule, any material,
491 compound, mixture, or preparation containing not more than 1 milligram of
492 difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
493 any salts of any of them.
- 494 (ii) Unless specifically excepted or unless listed in another schedule, any material,
495 compound, mixture, or preparation which contains any quantity of the following
496 substances, including its salts, isomers, and salts of isomers when the existence of
497 the salts, isomers, and salts of isomers is possible within the specific chemical
498 designation:
- 499 (A) Alprazolam;
500 (B) Barbital;
501 (C) Bromazepam;
502 (D) Butorphanol;
503 (E) Camazepam;
504 (F) Carisoprodol;
505 (G) Chloral betaine;
506 (H) Chloral hydrate;

507 (I) Chlordiazepoxide;
508 (J) Clobazam;
509 (K) Clonazepam;
510 (L) Clorazepate;
511 (M) Clotiazepam;
512 (N) Cloxazolam;
513 (O) Delorazepam;
514 (P) Diazepam;
515 (Q) Dichloralphenazone;
516 (R) Estazolam;
517 (S) Ethchlorvynol;
518 (T) Ethinamate;
519 (U) Ethyl loflazepate;
520 (V) Fludiazepam;
521 (W) Flunitrazepam;
522 (X) Flurazepam;
523 (Y) Halazepam;
524 (Z) Haloxazolam;
525 (AA) Ketazolam;
526 (BB) Loprazolam;
527 (CC) Lorazepam;
528 (DD) Lormetazepam;
529 (EE) Mebutamate;
530 (FF) Medazepam;
531 (GG) Meprobamate;
532 (HH) Methohexital;
533 (II) Methylphenobarbital (mephobarbital);
534 (JJ) Midazolam;
535 (KK) Nimetazepam;
536 (LL) Nitrazepam;
537 (MM) Nordiazepam;
538 (NN) Oxazepam;
539 (OO) Oxazolam;
540 (PP) Paraldehyde;

- 541 (QQ) Pentazocine;
542 (RR) Petrichloral;
543 (SS) Phenobarbital;
544 (TT) Pinazepam;
545 (UU) Prazepam;
546 (VV) Quazepam;
547 (WW) Temazepam;
548 (XX) Tetrazepam;
549 (YY) Tramadol;
550 (ZZ) Triazolam;
551 (AAA) Zaleplon; and
552 (BBB) Zolpidem.
- 553 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
554 any quantity of the following substances, including its salts, isomers whether
555 optical, position, or geometric, and salts of the isomers when the existence of the
556 salts, isomers, and salts of isomers is possible.
- 557 (iv) Unless specifically excepted or unless listed in another schedule, any material,
558 compound, mixture, or preparation which contains any quantity of the following
559 substances having a stimulant effect on the central nervous system, including its
560 salts, isomers whether optical, position, or geometric isomers, and salts of the
561 isomers when the existence of the salts, isomers, and salts of isomers is possible
562 within the specific chemical designation:
- 563 (A) Cathine ((+)-norpseudoephedrine);
564 (B) Diethylpropion;
565 (C) Fencamfamine;
566 (D) Fenproporex;
567 (E) Mazindol;
568 (F) Mefenorex;
569 (G) Modafinil;
570 (H) Pemoline, including organometallic complexes and chelates thereof;
571 (I) Phentermine;
572 (J) Pipradrol;
573 (K) Sibutramine; and
574 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

(vi) A drug product or preparation that contains any component of marijuana and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule IV of the federal Controlled Substances Act, Title II, P.L. 91-513.

(e) Schedule V:

(i) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

(B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(D) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

(E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;

(F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; and

(G) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

(ii) A drug product or preparation that contains any component of marijuana, including cannabidiol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.

(iii) Gabapentin.

Section 2. **Repealer.**

609 This bill repeals:
610 Section **4-45-101, Title.**
611 Section **4-45-102, Definitions.**
612 Section **4-45-103, Factual basis for claim as kratom product required -- Administrative**
613 **penalty -- Request for hearing.**
614 Section **4-45-104, Kratom processor requirements -- Criminal penalty.**
615 Section **4-45-105, Prohibition on sale to minors -- Criminal penalty.**
616 Section **4-45-106, Civil action available.**
617 Section **4-45-107, Rulemaking.**
618 Section **4-45-108, Registration of kratom products -- Department duties.**
619 Section 3. **Effective Date.**
620 This bill takes effect on May 6, 2026.